1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity

Journal of Cardiology

Volumn 64, Issue 4, 2014, Pages 297-301

  Ikeda, Nobutaka ^a   Hara, Hisao ^a   Hiroi, Yukio ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

1,5 Anhydro d glucitol; Coronary artery disease; Hemoglobin A1c; SYNTAX score

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; 1,5-ANHYDROGLUCITOL; BIOLOGICAL MARKER; DEOXYGLUCOSE; GLYCOSYLATED HEMOGLOBIN;

AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SYNTAX SCORE; BLOOD; COMPARATIVE STUDY; REGRESSION ANALYSIS;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DEOXYGLUCOSE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84924290057     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.02.014     Document Type: Article

References (31)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035-2038.
2. ADA Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
3. ADA Standards of medical care in diabetes - 2009. Diab Care 2009, 32(Suppl. 1):S13-S61.
4. Phillipou G., Phillips P.J. Intraindividual variation of glycohemoglobin: implications for interpretation and analytical goals. Clin Chem 1993, 39:2305-2308.
5. Rohlfing C., Wiedmeyer H.M., Little R., Grotz V.L., Tennill A., England J., Madsen R., Goldstein D. Biological variation of glycohemoglobin. Clin Chem 2002, 48:1116-1118.
6. Selvin E., Crainiceanu C.M., Brancati F.L., Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007, 167:1545-1551.
7. Irie Y., Sakamoto K., Kubo F., Okusu T., Katura T., Yamamoto Y., Umayahara Y., Katakami N., Kaneto H., Kashiyama T., Ueda Y., Kosugi K. Association of coronary artery stenosis with carotid atherosclerosis in asymptomatic type 2 diabetic patients. J Atheroscler Thromb 2011, 18:337-344.
8. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010, 123:S3-S11.
9. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., Coresh J., Brancati F.L. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
10. Ikeda N., Iijima R., Hara H., Moroi M., Nakamura M., Sugi K. Glycated hemoglobin is associated with the complexity of coronary artery disease, even in non-diabetic adults. J Atheroscler Thromb 2012, 19:1066-1072.
11. Erlinger T.P., Brancati F.L. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diab Care 2001, 24:1734-1738.
12. Bonora E., Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001, 44:2107-2114.
13. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003, 46(Suppl. 1):M9-M16.
14. Yamanouchi T., Akanuma Y. Serum 1,5-anhydroglucitol (1,5 ag): new clinical marker for glycemic control. Diab Res Clin Pract 1994, 24(Suppl.):S261-S268.
15. Dungan K.M. 1,5-Anhydroglucitol (glycomark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008, 8:9-19.
16. Dungan K.M., Buse J.B., Largay J., Kelly M.M., Button E.A., Kato S., Wittlin S. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diab Care 2006, 29:1214-1219.
17. Watanabe M., Kokubo Y., Higashiyama A., Ono Y., Miyamoto Y., Okamura T. Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 2011, 216:477-483.
18. Kashiwagi A., Kasuga M., Araki E., Oka Y., Hanafusa T., Ito H., Tominaga M., Oikawa S., Noda M., Kawamura T., Sanke T., Namba M., Hashiramoto M., Sasahara T., Nishio Y., et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diab Invest 2012, 3:39-40.
19. Sianos G., Morel M.A., Kappetein A.P., Morice M.C., Colombo A., Dawkins K., van den Brand M., Van Dyck N., Russell M.E., Mohr F.W., Serruys P.W. The syntax score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1:219-227.
20. Tapp R.J., Shaw J.E., Zimmet P.Z., Balkau B., Chadban S.J., Tonkin A.M., Welborn T.A., Atkins R.C. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004, 44:792-798.
21. Donahue R.P., Abbott R.D., Reed D.M., Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu heart program. Diabetes 1987, 36:689-692.
22. Rodriguez B.L., Lau N., Burchfiel C.M., Abbott R.D., Sharp D.S., Yano K., Curb J.D. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu heart program. Diabetes Care 1999, 22:1262-1265.
23. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H., Probstfield J.L., Simons-Morton D.G., Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Group AtCCRiDS.
24. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
25. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
26. Scherff F., Vassalli G., Sürder D., Mantovani A., Corbacelli C., Pasotti E., Klersy C., Auricchio A., Moccetti T., Pedrazzini G.B. The syntax score predicts early mortality risk in the elderly with acute coronary syndrome having primary pci. J Invasive Cardiol 2011, 23:505-510.
27. Brito J., Teles R., Almeida M., de Araújo Gonçalves P., Raposo L., Sousa P., Mendes M. Predictive value of syntax score in risk stratification of patients undergoing unprotected left main coronary artery angioplasty. J Invasive Cardiol 2011, 23:494-499.
28. Serruys P.W., Morice M.C., Kappetein A.P., Colombo A., Holmes D.R., Mack M.J., Ståhle E., Feldman T.E., van den Brand M., Bass E.J., Van Dyck N., Leadley K., Dawkins K.D., Mohr F.W., Investigators S. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009, 360:961-972.
29. Farooq V., Brugaletta S., Serruys P.W. The syntax score and syntax-based clinical risk scores. Semin Thorac Cardiovasc Surg 2011, 23:99-105.
30. Taggart D.P. Lessons learned from the syntax trial for multivessel and left main stem coronary artery disease. Curr Opin Cardiol 2011, 26:502-507.
31. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.